Preventive Cardiology | Links Medicus Content Curation & Alerts in Medicine

M-A | Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and CKD

1 Feb, 2023 | 13:06h | UTC

Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis – Pharmacology

WHO | Five billion people unprotected from trans-fat leading to heart disease

24 Jan, 2023 | 14:44h | UTC

News Release: Five billion people unprotected from trans fat leading to heart disease – World Health Organization

Report: Countdown to 2023: WHO report on global trans-fat elimination 2022 – World Health Organization

Commentary: Five Billion People Exposed to Industrially Produced Trans Fats – Health Policy Watch

Brazil and Peru join growing number of countries in the Americas that are eliminating industrially produced trans fats – Pan American Health Association / World Health Organization

WHO: More than 3 billion people protected from harmful trans-fat in their food

Action Package: WHO Plan to Eliminate Trans-fatty Acids from Global Food Supply

WHO Draft Guideline: Saturated Fatty Acid and Trans-fatty Intake for Adults and Children

Banning trans fats in New York prevented thousands of heart attacks

Review | Cardiovascular outcomes in type 1 and type 2 diabetes

23 Jan, 2023 | 13:18h | UTC

Cardiovascular outcomes in type 1 and type 2 diabetes – Diabetologia

Commentary on Twitter

Useful review of Cardiovascular outcomes in type 1 and type 2 diabeteshttps://t.co/mDECkFbZCq pic.twitter.com/q7J74FkNgJ

— Prof Kamlesh Khunti (@kamleshkhunti) January 20, 2023

Article under a http://creativecommons.org/licenses/by/4.0/. License

M-A | Prospective association of daily steps with cardiovascular disease

10 Jan, 2023 | 14:29h | UTC

Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis – Circulation (link to abstract – $ for full-text)

Commentaries:

CVD Benefits of Activity Seen Below Widely Quoted Step Goal in Older Adults – TCTMD

Heart health tip for older adults in 2023: Step it up a bit – University of Massachusetts Amherst

Commentary on Twitter

#OriginalResearch: In a meta-analysis of 8 studies, 6,000 to 9,000 steps/day was associated with 40% to 50% lower risk of CVD among older adults #AHAJournals https://t.co/fEA1EFyhTI pic.twitter.com/T6LXFGZoVb

— Circulation (@CircAHA) December 21, 2022

Cohort Study | Association of the triglyceride glucose index as a measure of insulin resistance with mortality and CVD

9 Jan, 2023 | 13:42h | UTC

Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study – The Lancet Health Longevity

Invited Commentary: The triglyceride glucose index and cardiovascular disease outcomes – The Lancet Health Longevity

RCT | Chlorthalidone (12.5-25 mg) and Hydrochlorothiazide (25-50 mg) are similarly effective for the prevention of CVD in hypertensive patients.

16 Dec, 2022 | 13:49h | UTC

Chlorthalidone vs. Hydrochlorothiazide for Hypertension–Cardiovascular Events – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: ‘Burden-free’ study method finds two blood pressure drugs equally effective – Veterans Affairs Research Communications

Related (news release and commentaries before publication): RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.

Commentary on Twitter

Patients 65 years or older with hypertension who switched from chlorthalidone to hydrochlorothiazide did not have fewer major cardiovascular events or non–cancer-related deaths than those who continued receiving hydrochlorothiazide. https://t.co/9xAiSZzxio pic.twitter.com/bIVOOiVDve

— NEJM (@NEJM) December 14, 2022

Cohort Study | Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood.

9 Dec, 2022 | 13:11h | UTC

Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood – Circulation

Commentary: Lp(a) in Youth and Risk of ASCVD Outcomes in Adulthood – American College of Cardiology

Commentary on Twitter

#OriginalResearch Childhood Lp(a) levels are associated with significantly increased risk of develping ASCVD as adults @UTUpophealth @olraita #AHAJournals https://t.co/oqHv19QU6l pic.twitter.com/ByZmtRrXqy

— Circulation (@CircAHA) November 30, 2022

Cohort Study | Adding salt to foods linked to increased risk of cardiovascular disease.

6 Dec, 2022 | 14:04h | UTC

Adding Salt to Foods and Risk of Cardiovascular Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)

News Release: Shaking less salt on your food at the table could reduce heart disease risk – American College of Cardiology

Commentaries:

Adding Salt to Food and Risk of Cardiovascular Disease – American College of Cardiology

Lower Frequency of Adding Salt to Food Linked to Lower CVD Risk – HealthDay

M-A | Cardioprotective effects of influenza vaccination in patients with high risk of cardiovascular disease.

25 Nov, 2022 | 12:47h | UTC

Cardioprotective effects of influenza vaccination among patients with established cardiovascular disease or at high cardiovascular risk: a systematic review and meta-analysis – European Journal of Preventive Cardiology (free for a limited period)

RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.

RCT | A double-dose influenza vaccination during hospitalization for acute coronary syndrome did not improve outcomes compared to standard-dose outpatient vaccination.

Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.

23 Nov, 2022 | 14:02h | UTC

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease – Journal of the American College of Cardiology

Editorial: HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity? – Journal of the American College of Cardiology

News Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health

Commentary: Study suggests that HDL or ‘good’ cholesterol is less beneficial than previously thought, especially for Black adults – CNN

Cohort Study | Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease.

23 Nov, 2022 | 13:55h | UTC

Polygenic risk score improves the accuracy of a clinical risk score for coronary artery disease – BMC Medicine

AHA Scientific Statement | Polygenic risk scores for cardiovascular disease.

Incremental Value of Polygenic Risk Scores in Primary Prevention of Coronary Heart Disease: A Review – JAMA Internal Medicine

Cohort Study | Predictive utility of a validated polygenic risk score for long-term risk of coronary heart disease in young and middle-aged adults.

Cohort Study | Polygenic risk, midlife life’s simple 7, and lifetime risk of stroke.

Cohort Study: A polygenic risk score may improve risk stratification of coronary artery disease.

Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.

Studies: Little Benefit from Polygenic Risk Score vs. Clinical Risk Score for Predicting Cardiovascular Risk

Commentary on Twitter

A #Polygenic risk score improves the accuracy of a clinical risk score for #CoronaryArteryDisease

Read more about improved predictive accuracy for incident CAD in the #UKBiobank at #BMCMedicine https://t.co/8T5RaacnTj pic.twitter.com/vIhg9IGhRv

— BMC Medicine (@BMCMedicine) November 8, 2022

RCT | Comparative effects of low-dose rosuvastatin vs. dietary supplements on lipids and inflammatory biomarkers.

16 Nov, 2022 | 13:41h | UTC

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers – Journal of the American College of Cardiology

News Release: 6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins – American Heart Association

Commentaries:

Study – For Lowering Cholesterol, Statins Work, Supplements Don’t – Science-Based Medicine

Statins vs. supplements: New study finds one is ‘vastly superior’ to cut cholesterol – NPR

Cohort Study | Childhood adversity and cardiovascular disease in early adulthood.

16 Nov, 2022 | 13:29h | UTC

Childhood adversity and cardiovascular disease in early adulthood: a Danish cohort study – European Heart Journal (free for a limited period)

Commentary: Study explores the links between childhood adversity and cardiovascular disease in early adulthood – European Society of Cardiology/News Medical

Commentary from the author on Twitter

https://twitter.com/HulvejRod/status/1592520830155886593

Canadian guideline for the prevention and management of cardiovascular disease in primary care.

8 Nov, 2022 | 12:37h | UTC

Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update – Canadian Medical Association Journal

News Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal

RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.

7 Nov, 2022 | 12:54h | UTC

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)

News Releases:

New medicine reduces triglyceride by 25%, no change in CVD risk in people with Type 2 diabetes – American Heart Association

Triglyceride-lowering trial neutral for cardiovascular event reduction – Brigham and Women’s Hospital

Commentaries:

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD

PROMINENT: Pemafibrate Effective in Lowering Tryglycerides, But Not Reducing Risk of CV Events – American College of Cardiology

Commentary on Twitter

In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv

— NEJM (@NEJM) November 5, 2022

Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.

1 Nov, 2022 | 12:02h | UTC

Severity of obstructive coronary artery stenosis after pre-eclampsia – Heart

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine

Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study – Journal of the American Heart Association

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Gestational Hypertension and Future Risk of Cardiovascular Disease

Research: Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents

M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.

26 Oct, 2022 | 14:32h | UTC

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis – eClinicalMedicine

Commentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News

Cohort Study | Associations of hypertriglyceridemia onset age with cardiovascular disease and all‐cause mortality in adults.

20 Oct, 2022 | 12:25h | UTC

Associations of Hypertriglyceridemia Onset Age With Cardiovascular Disease and All‐Cause Mortality in Adults: A Cohort Study – Journal of the American Heart Association

RCT | Combination of pitavastatin and ezetimibe vs. monotherapy of pitavastatin in patients with primary hypercholesterolemia.

19 Oct, 2022 | 14:15h | UTC

A Multicenter, Randomized, Double-Blind, Active-Controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia – Clinical Therapeutics

Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.

18 Oct, 2022 | 12:58h | UTC

Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)

Perspective | The polypill: from concept and evidence to implementation.

18 Oct, 2022 | 12:55h | UTC

The polypill: from concept and evidence to implementation – The Lancet (free registration required)

News Release: The polypill could avoid millions of premature deaths, heart attacks and strokes every year, say leading cardiology experts – McMaster University

#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.

#ESCCongress – M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention.

Opinion: A new important study supports wider use of the polypill

#AHA20 – Randomized trial: A polypill comprising statins, multiple blood pressure lowering drugs, and aspirin prevents cardiovascular events among patients at intermediate cardiovascular risk

Perspective: Are Polypills and Population-based Treatment the Next Big Things?

The Polypill Revisited: Why We Still Need Population-Based Approaches in the Precision Medicine Era

Randomized Trial: Polypill for Cardiovascular Disease Prevention in an Underserved Population

Randomized Trial: Effectiveness of Polypill for Primary and Secondary Prevention of Cardiovascular Diseases

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology – Global Heart

Perspective: The Polypill and the Long Journey to Major Impact

Research: Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

Cohort Study | Purpose in life (Ikigai) and employment status in relation to cardiovascular mortality.

14 Oct, 2022 | 14:06h | UTC

Purpose in life (Ikigai) and employment status in relation to cardiovascular mortality: the Japan Collaborative Cohort Study – BMJ Open

RCT | Allopurinol does not improve outcomes in patients with ischemic heart disease without previous gout.

13 Oct, 2022 | 13:53h | UTC

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Invited Commentary: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Commentary on Twitter

Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle

— Pradeep Natarajan (@pnatarajanmd) October 7, 2022

Under a Creative Commons Attribution (CC BY 4.0) License